Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

by Sheikh, Sarah , Olsson, Tina , Stukalin, Ellie , Dauvilliers, Yves , Tanaka, Shinichiro , Taniguchi, Mitsutaka , Plazzi, Giuseppe , Kadali, Harisha , Naylor, Melissa , von Hehn, Christian , Lammers, Gert Jan , Khatami, Ramin , Cai, Alice , del Río Villegas, Rafael , Swick, Todd J. , Abraham, Anson , Lamberton, Marta , Mignot, Emmanuel , Hang, Yaming , von Rosenstiel, Philipp , Neuwirth, Rachel , Wang, Hao

in Administration, Oral / Adolescent / Adult / Agonists / Cataplexy / Cataplexy - epidemiology / Cataplexy - etiology / Cataplexy - prevention & control / Cerebrospinal fluid / Clinical Medicine / Clinical Medicine General / Double-Blind Method / Endocrinology / Endocrinology General / Female / Hallucinations / Humans / Incidence / Latency / Male / Middle Aged / Narcolepsy / Narcolepsy - complications / Narcolepsy - diagnosis / Narcolepsy - drug therapy / Neurology / Neurosurgery / Neurosurgery General / Orexin Receptors - agonists / Orexins / Outpatient-Based Clinical Medicine / Pediatrics / Pediatrics General / Placebos / Psychiatry / Psychiatry General / Quality of life / Sleep / Sleep and wakefulness / Sleep disorders / Sleep Initiation and Maintenance Disorders - chemically induced / Sleep Initiation and Maintenance Disorders - epidemiology / Sleep Latency - drug effects / Treatment Outcome / Urination - drug effects / Wakefulness - drug effects / Young Adult

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

2025

Confirm

Do you wish to request the book?

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

Sheikh, Sarah,

Olsson, Tina,

Stukalin, Ellie,

Dauvilliers, Yves,

Tanaka, Shinichiro,

Taniguchi, Mitsutaka,

Plazzi, Giuseppe,

Kadali, Harisha,

Naylor, Melissa,

von Hehn, Christian,

Lammers, Gert Jan,

Khatami, Ramin,

Cai, Alice,

del Río Villegas, Rafael,

Swick, Todd J.,

Abraham, Anson,

Lamberton, Marta,

Mignot, Emmanuel,

Hang, Yaming,

von Rosenstiel, Philipp,

Neuwirth, Rachel,

Wang, Hao

2025

Overview

In this phase 2 randomized, placebo-controlled trial involving 112 participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Adult

/ Cataplexy - epidemiology

/ Cataplexy - etiology